Oral Delivery of Methylthioadenosine to the Brain Employing Solid Lipid Nanoparticles: Pharmacokinetic, Behavioral, and Histopathological Evidences
- 171 Downloads
The present study aimed to orally deliver methylthioadenosine (MTA) to the brain employing solid lipid nanoparticles (SLNs) for the management of neurological conditions like multiple sclerosis. The stearic acid–based SLNs were below 100 nm with almost neutral zeta potential and offered higher drug entrapment and drug loading. Cuprizone-induced demyelination model in mice was employed to mimic the multiple sclerosis–like conditions. It was observed that the MTA-loaded SLNs were able to maintain the normal metabolism, locomotor activity, motor coordination, balancing, and grip strength of the rodents in substantially superior ways vis-à-vis plain MTA. Histopathological studies of the corpus callosum and its subsequent staining with myelin staining dye luxol fast blue proved the potential of MTA-loaded SLNs in the remyelination of neurons. The pharmacokinetic studies provided the evidences for improved bioavailability and enhanced bioresidence supporting the pharmacodynamic findings. The studies proved that SLN-encapsulated MTA can be substantially delivered to the brain and can effectively remyelinate the neurons. It can reverse the multiple sclerosis–like symptoms in a safer and effective manner, that too by oral route.
KEY WORDSmultiple sclerosis brain delivery lipid-based systems remyelination safety
The financial support from the Central University of Rajasthan, Bandar Sindri, Distt., Ajmer, India, is duly acknowledged.
Compliance with Ethical Standards
All the animal protocols were duly approved by the Animal Ethics Committee, Panjab University, Chandigarh, and the studies were performed in strict accordance to the guidelines laid by the University in accordance with the apt national regulations.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.Warren S, Warren KG. Multiple sclerosis. Malta: World Health Organization; 2001.Google Scholar
- 2.Kumar P, Sharma G, Gupta V, Kaur R, Thakur K, Malik R, et al. Preclinical explorative assessment of dimethyl fumarate-based biocompatible nanolipoidal carriers for the management of multiple sclerosis. ACS Chem Neurosci. 2018;9:1152–8. https://doi.org/10.1021/acschemneuro.7b00519.CrossRefPubMedGoogle Scholar
- 8.Kumar P, Sharma G, Kumar R, Malik R, Singh B, Katare OP, et al. Enhanced brain delivery of dimethyl fumarate employing tocopherol-acetate-based nanolipidic carriers: evidence from pharmacokinetic, biodistribution, and cellular uptake studies. ACS Chem Neurosci. 2017;8:860–5. https://doi.org/10.1021/acschemneuro.6b00428.CrossRefPubMedGoogle Scholar
- 9.Kumar P, Sharma G, Kumar R, Singh B, Malik R, Katare OP, et al. Promises of a biocompatible nanocarrier in improved brain delivery of quercetin: biochemical, pharmacokinetic and biodistribution evidences. Int J Pharm. 2016;515:307–14. https://doi.org/10.1016/j.ijpharm.2016.10.024.CrossRefPubMedGoogle Scholar
- 10.Raza K, Singh B, Lohan S, Sharma G, Negi P, Yachha Y, et al. Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity. Int J Pharm. 2013;456:65–72. https://doi.org/10.1016/j.ijpharm.2013.08.019.CrossRefPubMedGoogle Scholar
- 16.Matsushima GK, Morell P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 2001;11:107–116.Google Scholar
- 17.Masserini M. Nanoparticles for brain drug delivery. ISRN Biochem. 2013;Article ID 238428, 18 pages. https://doi.org/10.1155/2013/238428.
- 19.Raza K, Negi P, Takyar S, Shukla A, Amarji B, Katare OP. Novel dithranol phospholipid microemulsion for topical application: development, characterization and percutaneous absorption studies. J Microencapsul. 2011;28(3):190–9. https://doi.org/10.3109/02652048.2010.546435.CrossRefPubMedGoogle Scholar
- 20.Raza K, Kumar P, Kumar N, Malik R. Pharmacokinetics and biodistribution of the nanoparticles. In Advances in nanomedicine for the delivery of therapeutic nucleic acids 2017 (pp. 165–186).Google Scholar
- 21.Zendedel A, Beyer C, Kipp M. Cuprizone induced demyelination as a tool to study remyelination and axonal protection. J Mol Neurosci. 51:567–72.Google Scholar